The paradoxical effect of oral prednisone in granulomatous lobular mastitis: An observational cohort study
PLOS One · 08.04.2026 · 21 (4) · e0341901
DOI: 10.1371/journal.pone.0341901 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS One, online erschienen am 08.04.2026. Verfasst von Haiyan Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Breast Centre, West China Second University Hospital, Chengdu, China. Hauptthemen laut MEDLINE: Prednisone, Granulomatous Mastitis. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Despite being a cornerstone therapy for granulomatous lobular mastitis (GLM), the use of oral prednisone lacks a standardized protocol due to undefined optimal parameters and insufficient large-scale evidence regarding its impact on disease recurrence.
Objectives
The retrospective cohort study comprehensively assessed the efficacy of oral prednisone for GLM by utilizing a large-scale cohort. It aimed to identify the optimal therapeutic protocol, with the ultimate aim of establishing a robust evidence base to inform standardized clinical guidelines.
Methods
A cohort of 614 patients diagnosed with GLM was included in this study from January 2017 to December 2024. A three-dimensional evaluation of treatment timing (symptom-to-treatment interval), duration, and initial dosage (both absolute and weight-adjusted) was performed to identify prognostic factors and optimal cutoffs.
Results
Oral prednisone was identified as an independent risk factor for recurrence (HR = 2.534, 95% CI: 1.615–3.975, P < 0.001). Survival curve analysis revealed that the 1-year recurrence rate was significantly higher in the oral prednisone group than in the non-prednisone group (29.4% vs. 14.6%, P = 0.001). Subgroup analysis showed that the long-interval, low-dose group (symptom-to-treatment interval > 6 weeks, dosage ≤ 0.4 mg/kg/day) yielded the most favorable results. The one-year recurrence rate of this group (6.2%) was significantly lower than other groups (all P < 0.05) and comparable to the non-prednisone group (14.6%, P = 0.233). Conversely, the short-interval group (symptom-to-treatment interval: 0–6 weeks) demonstrated the highest one-year relapse rate (33.5%), significantly exceeding that of the non-prednisone group (P < 0.001).
Conclusions
While oral prednisone therapy may be associated with an increased relapse risk in GLM, an optimized protocol—initiating treatment after a 6-week symptom interval at a dose of ≤ 0.4 mg/kg/day—was identified to mitigate this risk. These findings highlight the paramount importance of treatment timing and dosage, offering a data-driven strategy to refine current therapeutic practices. Prospective studies are warranted to validate this proposed regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Breast Centre, West China Second University Hospital, Chengdu, China.
- Department of Breast and Thyroid, Sichuan Provincial Hospital for Women and Children (Affiliated Women and Children's Hospital of Chengdu Medical College), Chengdu, China.
ORCID-Profile: Jing Luo
Zitieren
APA
Zhang, H., Wu, R., Chen, J., Feng, J., & Luo, J. (2026). The paradoxical effect of oral prednisone in granulomatous lobular mastitis: An observational cohort study. PLOS One, 21(4), e0341901. https://doi.org/10.1371/journal.pone.0341901
Vancouver
Zhang H, Wu R, Chen J, Feng J, Luo J. The paradoxical effect of oral prednisone in granulomatous lobular mastitis: An observational cohort study. PLOS One. 2026;21(4):e0341901. doi:10.1371/journal.pone.0341901
BibTeX
@article{Zhang2026,
author = {Zhang, Haiyan and Wu, Ruiyang and Chen, Jin and Feng, Jinyan and Luo, Jing},
title = {The paradoxical effect of oral prednisone in granulomatous lobular mastitis: An observational cohort study},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {4},
pages = {e0341901},
doi = {10.1371/journal.pone.0341901}
}
EUVIMED